Letter to the Editor

COVID-19 Patient Acceptance to Monoclonal Antibody Infusion: A Single Medical Center Experience

Authors: Angie Ton, MD, Dawn Francis, MD, MHS, Leigh Speicher, MD, MPH

Abstract

To the Editor: As emergency departments and hospitals have become inundated with patients with coronavirus disease 2019 (COVID-19), several treatment modalities have been investigated to help improve COVID-19 symptoms and reduce hospitalizations. Bamlanivimab was approved under Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) on November 10, 2020.1 Administration of casirivimab and imdevimab together also was approved shortly after on November 21, 2020.2 After FDA approval for EUA, these medications were released by the federal government to the states. Each state then determined how many doses it would send to meet the requests of interested medical systems.
Posted in: Infectious Disease143

Full Article

Having trouble viewing the article content below? Click here to open it directly.

References

1. US Food and Drug Administration, Center for Drug Evaluation and Research. Bamlanivimab EUA letter of authorization. www.fda.gov/ media/143602/download. Published November 10, 2020.Accessed November 11, 2020.
 
2. US Food and Drug Administration, Center for Drug Evaluation and Research. Casirivimab and imdevimab EUA letter of authorization. https://www.fda.gov/media/143891/download. Published November 21, 2020. Accessed November 22, 2020.
 
3. Jethwa T, Ton A, Paredes C, et al. Establishing Mayo Clinic’s coronavirus disease 2019 virtual clinic: a preliminary communication. Telemed J E Health 2020;26:1419–1423.